TG Therapeutics Stock Forecast for 2023 - 2025 - 2030

Updated on 05/27/2023

Stock Rating
9
Price Target
$19.00
Consensus
Outperform
Downside
-30.15%
Analysts
1
Stock Rating
9
Downside
-30.15%
Analysts
1
Price Target
$19.00

TG Therapeutics Stock Forecast and Price Target

The average price target for TG Therapeutics's stock set by recognized analysts recently is $19.00, which would result in a potential downside of approximately -30.15% if it reached this mark. The estimation is based on a high estimate of $40.00 and a low estimate of $4.00.

$19.00

-30.15% Downside

Outperform
Outperform

TG Therapeutics Fair Value Forecast for 2023 - 2025 - 2030

TG Therapeutics's Price has grown In the last two years, rising from $0.00 to $0.00 – a growth of 100.00%. In the next year, analysts believe that Fair Value will reach $25.96 – an increase of 100.00%. For the next nine years, experts predict that TG Therapeutics's Fair Value will grow at a rate of 100.00%.

2022 Fair Value Forecast
$25.96
2023 Fair Value Forecast
$29.00
2024 Fair Value Forecast
$32.25
2025 Fair Value Forecast
$35.86
2026 Fair Value Forecast
$39.87
2027 Fair Value Forecast
$44.33
2028 Fair Value Forecast
$49.29
2029 Fair Value Forecast
$54.81
2030 Fair Value Forecast
$60.94

TG Therapeutics Revenue Forecast for 2023 - 2025 - 2030

TG Therapeutics's Revenue has grown In the last three years, rising from $150.00k to $2.79M – a growth of 1760.00%. In the next year, analysts believe that Revenue will reach $3.18M – an increase of 14.01%. For the next eight years, experts predict that TG Therapeutics's Revenue will grow at a rate of 47.88%.

2023 Rev Forecast
$0.00B
2024 Rev Forecast
$0.00B
2025 Rev Forecast
$0.00B
2026 Rev Forecast
$0.00B
2027 Rev Forecast
$0.00B
2028 Rev Forecast
$0.00B
2029 Rev Forecast
$0.00B
2030 Rev Forecast
$0.00B

TG Therapeutics Dividend per Share Forecast for 2023 - 2025 - 2030

TG Therapeutics Free Cash Flow Forecast for 2023 - 2025 - 2030

In the last three years, TG Therapeutics's Free Cash Flow has grown, moving from $-132.94M to $-312.54T – an increase of 235100697.35%. 0 analysts predict TG Therapeutics's Free Cash Flow will decrease by 55.18% in the next year, reaching $-140.07T. By 2030, professionals predict that TG Therapeutics's Free Cash Flow will decrease by 42.71%, to $-179.05T.

2023 FCF Forecast
$-1.400713545E+14
2024 FCF Forecast
$-1.3806833413065E+14
2025 FCF Forecast
$-1.4938073297375E+14
2026 FCF Forecast
$-2.0764419819128E+14
2027 FCF Forecast
$-1.8398660254402E+14
2028 FCF Forecast
$-1.7002201941093E+14
2029 FCF Forecast
$-1.6606050635866E+14
2030 FCF Forecast
$-1.7904643795591E+14

TG Therapeutics Net Income Forecast for 2023 - 2025 - 2030

In the last three years, TG Therapeutics's Net Income has grown by 14.73%, rising from $-172.87M to $-198.34M. For the next year, analysts predict that Net Income will reach $-210.01M – an increase of 5.88%. Over the next eight years, experts believe that TG Therapeutics's Net Income will grow at a rate of 30.51%.

2023 NI Forecast
$-210009003.33
2024 NI Forecast
$-245157510.19
2025 NI Forecast
$-290601540.66
2026 NI Forecast
$-256174944.81
2027 NI Forecast
$-242051166.19
2028 NI Forecast
$-244988053.67
2029 NI Forecast
$-259752667.04
2030 NI Forecast
$-258852191.13

TG Therapeutics EBITDA Forecast for 2023 - 2025 - 2030

In the last three years, TG Therapeutics's EBITDA has seen an increase, rising from $-168.96M to $-188.14M. This represents a growth of 11.35%. Analysts predict that TG Therapeutics's EBITDA will increase in the upcoming year, reaching $-203.36M. This would represent an increase of 8.09%. Over the next eight years, experts predict that TG Therapeutics's EBITDA will grow at a rate of 35.25%.

2023 EBITDA Forecast
$-203360526.00
2024 EBITDA Forecast
$-240643289.10
2025 EBITDA Forecast
$-288876225.68
2026 EBITDA Forecast
$-250677159.44
2027 EBITDA Forecast
$-236513899.93
2028 EBITDA Forecast
$-240085259.82
2029 EBITDA Forecast
$-255882869.91
2030 EBITDA Forecast
$-254458455.27

TG Therapeutics EBIT Forecast for 2023 - 2025 - 2030

TG Therapeutics's EBIT has seen growth In the last two years, going from $-169.06M to $-344.77M – a gain of 103.93% In the following year, the 0 analysts surveyed believe that TG Therapeutics's EBIT will decrease by 26.50%, reaching $-253.39M. According to professionals, by 2030, TG Therapeutics's EBIT will have decreased by 21.86%, falling down to $-269.41M.

2022 EBIT Forecast
$-253394457.67
2023 EBIT Forecast
$-234136478.88
2024 EBIT Forecast
$-252586433.42
2025 EBIT Forecast
$-283730340.66
2026 EBIT Forecast
$-274225374.25
2027 EBIT Forecast
$-260687781.61
2028 EBIT Forecast
$-258671796.10
2029 EBIT Forecast
$-266811335.28
2030 EBIT Forecast
$-269408298.94

TG Therapeutics EPS Price Prediction Forecast for 2023 - 2025 - 2030

TG Therapeutics's EPS has grown In the last two years, rising from $-1.96 to $-2.63 – a growth of 34.18%. In the next year, 0 analysts estimate that TG Therapeutics's EPS will decrease by 11.66%, reaching $-2.32. According to professional forecasts, in 2030, TG Therapeutics's EPS will decrease by 10.44%, reaching $-2.36.

2022 EPS Forecast
$-2.32
2023 EPS Forecast
$-2.22
2024 EPS Forecast
$-2.29
2025 EPS Forecast
$-2.40
2026 EPS Forecast
$-2.38
2027 EPS Forecast
$-2.32
2028 EPS Forecast
$-2.31
2029 EPS Forecast
$-2.34
2030 EPS Forecast
$-2.36